Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The share is getting closer to its long-term support in weekly data, at EUR 5.47, which offers good timing for buyers.
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 38% by 2022.
  • The company is in a robust financial situation considering its net cash and margin position.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • Low profitability weakens the company.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
POXEL-50.82%199
GILEAD SCIENCES, INC.-10.51%72 904
REGENERON PHARMACEUTICALS44.76%57 199
VERTEX PHARMACEUTICALS-4.84%54 210
WUXI APPTEC CO., LTD.71.31%40 863
BEIGENE, LTD.78.89%26 872
GENMAB A/S43.71%21 783
BIONTECH SE151.95%20 330
HUALAN BIOLOGICAL ENGINEERI..89.36%13 962
MYOKARDIA, INC.206.69%11 919
-
ARGENX SE49.30%11 829
SAREPTA THERAPEUTICS, INC.5.34%10 671
MIRATI THERAPEUTICS, INC.68.51%10 584
NEUROCRINE BIOSCIENCES, INC..-8.21%9 201
ASCENDIS PHARMA A/S17.42%8 691
ULTRAGENYX PHARMACEUTICAL I..135.31%6 582
More Results
Financials
Sales 2020 14,7 M 17,1 M 17,1 M
Net income 2020 -28,0 M -32,6 M -32,6 M
Net cash 2020 21,6 M 25,2 M 25,2 M
P/E ratio 2020 -5,76x
Yield 2020 -
Capitalization 171 M 199 M 199 M
EV / Sales 2020 10,1x
EV / Sales 2021 2,47x
Nbr of Employees 51
Free-Float 75,3%
Upcoming event on POXEL
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes